Skip to content Skip to sidebar Skip to footer

Newsletter

Healthcare Stocks

Rhythm Biosciences’ ColoSTAT has been commercialised and the roll out will ramp up fast!

Rhythm Biosciences' colorectal cancer test ColoSTAT is officially on the market and has made its first sale. In our view, this could mark the beginning of a major few years for this company. What are the Best ASX Stocks to invest in right now? Check our buy/sell tips [sg_popup id="23914" event="click"][/sg_popup] ColoSTAT is commercialised, albeit not as investors…

ByNick SundichMarch 18, 2026

T-Cell Lymphoma is a very deadly cancer, but this ASX stock has a treatment in a Phase 2 trial!

Prescient Therapeutics' (ASX:PTX) trial of PTX-100 against T-Cell Lymphoma is well and truly underway now with 8 out of 16 trial sites set up. This significant milestone provides significant hope to sufferers of this disease as well as to the company's investors. What are the Best ASX Biotech Stocks to invest in right now? Check our…

ByNick SundichMarch 17, 2026

Same Theme, Better Choices: Here Are 5 ASX Stocks Not To Buy, And 5 To Buy Instead!

It is easy to think of ASX Stocks that are a compelling case to buy, but tougher to think of ASX Stocks Not To Buy. Often, people are lured into companies because they represent compelling thematic right now: surging gold prices, copper's electrification boom, resilient healthcare demand, and a quick-service restaurant sector that keeps growing. But not…

ByNick SundichMarch 17, 2026

Tetratherix (ASX: TTX) Surges 22% After Signing US$30 Million GLP-1 Deal: Is TTX a Buy Right Now?

Tetratherix jumps on new US GLP-1 deal Tetratherix (ASX: TTX) surged 22% on Monday after signing an exclusive deal with US consumer health company Superpower Health to develop a new precision medicine franchise. The agreement is immediately revenue-generating, which is a meaningful shift for a company that has not yet recorded commercial product sales. Under…

ByUjjwal MaheshwariMarch 17, 2026

Telix (ASX:TLX) Pixclara NDA Resubmitted, The FDA Clock Restarts

Pixclara Back With the FDA Telix has resubmitted its NDA to the FDA for Pixclala, its PET imaging agent for recurrent or progressive glioma, a common type of brain tumour. Pixclara is a targeted amino acid PET scan designed to help distinguish true tumour recurrence from treatment-related changes in adult patients. That is a real clinical…

ByCharlie YouldenMarch 16, 2026

Here are 5 ASX Biotech Targets Amidst The $230bn Patent Cliff; And Which Big Pharma Companies Could Buy Them!

There are plenty of ASX Biotech Targets that major pharmaceutical companies wanting to minimise the impact of the Patent Cliff could look at. For those who don't know what the patent cliff is, it is is one of the most consequential forces in global pharmaceuticals. The concept of a big pharma's drug losing exclusivity and having…

ByNick SundichMarch 16, 2026

Immutep’s Phase 3 trial for Efti has gotten the chop and shares plunge >90%! What now for investors?

After nearly a week in suspense, Immutep (ASX:IMM) confirmed news about Efti that its investors did not want to hear, and arguably feared more and more as the week with trading suspended went on. Namely, its most advanced clinical trial for Efti is all over red rover! While it is not the end of the company,…

ByNick SundichMarch 13, 2026

Orthocell (ASX: OCC) Lines Up UK Distributor for Remplir Ahead of Approval- Is Now the Time to Buy?

Orthocell Moves Closer to UK Growth Orthocell (ASX: OCC) just made a move that not every small-cap medtech company would make. Rather than waiting for regulatory approval before signing a UK distributor agreement, the company secured one early. On December 15, 2025, Orthocell submitted its application to the British Standards Institution seeking approval to sell…

ByUjjwal MaheshwariMarch 11, 2026

What does the 2026 health insurance premium rise mean for ASX health insurance stocks?

The 2026 health insurance premium rise is in, and it is 4.41%. It made headlines because it is ahead of inflation and the largest average increase in percentage terms since 2017. Obviously unwelcome timing for households struggling with the cost of living, but good for the companies themselves, right? Not so fast. What are the Best…

ByNick SundichMarch 10, 2026

Pro Medicus (ASX: PME) Falls Despite A$40m in US Renewals: Is This a Buying Opportunity?

Pro Medicus Dips Despite Strong Renewals Pro Medicus (ASX: PME) slipped around 1% on Monday despite announcing approximately A$40m in US contract renewals, including an expanded deal with MedStar Health and a third renewal from imaging group Zwanger-Pesiri at higher per-transaction fees. The pullback has nothing to do with the business itself. It is a…

ByUjjwal MaheshwariMarch 10, 2026

the Kick-ass Multipurpose WordPress Theme

Healthcare Stocks

Rhythm Biosciences’ ColoSTAT has been commercialised and the roll out will ramp up fast!

T-Cell Lymphoma is a very deadly cancer, but this ASX stock has a treatment in a Phase 2 trial!

Same Theme, Better Choices: Here Are 5 ASX Stocks Not To Buy, And 5 To Buy Instead!

Tetratherix (ASX: TTX) Surges 22% After Signing US$30 Million GLP-1 Deal: Is TTX a Buy Right Now?

Telix (ASX:TLX) Pixclara NDA Resubmitted, The FDA Clock Restarts

Here are 5 ASX Biotech Targets Amidst The $230bn Patent Cliff; And Which Big Pharma Companies Could Buy Them!

Immutep’s Phase 3 trial for Efti has gotten the chop and shares plunge >90%! What now for investors?

Orthocell (ASX: OCC) Lines Up UK Distributor for Remplir Ahead of Approval- Is Now the Time to Buy?

What does the 2026 health insurance premium rise mean for ASX health insurance stocks?

Pro Medicus (ASX: PME) Falls Despite A$40m in US Renewals: Is This a Buying Opportunity?

Stocks in Spotlight

Investing in the Year of the Rat

2020, the Golden Year

Market trouble spots to avoid in 2020

Healthcare Stocks

Stocks in Spotlight

Add Your Heading Text Here